Skip to content

Study · Case report or series · n = 1 · 2018

1 result

No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.

Sherman SI, Kloos RT, Tuttle RM, Pontecorvi A, Völzke H, Harper K, Vance C, Alston JT, Usborne AL, Sloop KW, Lakshmanan M

Diabetic medicine : a journal of the British Diabetic Association1 Mar 2018Cited by 10 (Europe PMC)

PMID28755389 (opens in a new tab)PMCIDPMC5838554 (opens in a new tab)DOI10.1111/dme.13437 (opens in a new tab)PepBankPUB-28755389
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman with T2DM and pre-existing medullary thyroid carcinoma, serum calcitonin did not change significantly during dulaglutide treatment.

    In plain wordsIn a woman with pre-existing thyroid cancer, calcitonin did not change significantly from before dulaglutide treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSerum calcitonin
    Study

    n = 1

    Comparator
    Before treatment
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    2.0 mg · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    This report presents the case of a woman with pre-existing medullary thyroid carcinoma who exhibited no significant changes in serum calcitonin levels despite treatment with dulaglutide 2.0 mg for 6 months in the Assessment of Weekly AdministRation of LY2189265 [dulaglutide] in Diabetes-5 clinical study (NCT00734474).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3Results postedNCT00734474

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Eli Lilly and Companyn = 1,202Aug 2008 to Jul 2012

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 20 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.